Zefei Li

Zefei Li

Auto-generated profile, based on publicly available information

Zefei Li

Hubei University of Chinese Medicine, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
YHYunlei Hou
Yunlei Hou
QSQi Shen
Qi Shen
ZLZefei Li
Zefei Li
Shaowei ChenShaowei Chen
Shaowei Chen
YZYanfang Zhao
Yanfang Zhao
PGPing Gong
Ping Gong

7 May 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
XWXinyue Wang
Xinyue Wang
YHYiran Hu
Yiran Hu
XZXinyu Zou
Xinyu Zou
PWPengfei Wang
Pengfei Wang
YHYue Hao
Yue Hao
PGPing Gong
Ping Gong

22 September 2023 in Medicine
Verified
Journal Article
Open access
ZLZefei Li
Zefei Li
HSHeyuan Shi
Heyuan Shi
We aim to investigate the mechanism and effective components of Shenghui decoction (SHD), which has been shown to inhibit acetylcholinesterase (AChE) through molecular docking (MD) and molecular dynamics simulation (MDS). The effective ingredients in SHD were collected through the TCMSP database and literature review. All components were docked with AChE using CDOCKER. Receptor ligand interaction analysis was performed for the optimal ligand. Two simulation models (model I and II) containing AChE and acetylcholine (ACh) were constructed, in which model II contained the best-docked ligand. Perform 90ns MDS on 2 models. After the simulation, the distance between ACh and AChE peripheral active sites were calculated in both models. The root mean square deviation (RMSD) curve of ligand and receptor, the radius of gyration (Rog) of the receptor, the distance between ligand center and binding site center, and the binding energy of ligand and receptor were calculated in model II. 98 ingredients of SHD were collected, and the best ligand was Tumulosic acid. The residues that form conventional hydrogen bonds between AChE and Tumulosic acid include Tyr132 and Glu201. MDS revealed that ACh could bind to AChE active site in model I. In model II, ACh cannot bind to the binding cavity because the ligand occupies the active site. The RMSD of AChE and Tumulosic acid tends to be stable, the Rog curve of AChE is relatively stable, and the distance between ligand and binding cavity does not fluctuate greatly, indicating that the structure of receptor and ligand is relatively stable. The binding energy of AChE and Tumulosic acid was −24.14 ± 2.46 kcal/mol. SHD contains many effective ingredients that may inhibit AChE activity. Tumulosic acid can occupy the binding site to prevent ACh from entering the chemical domain, thus exerting AChE inhibitory effect.

20 October 2023 in Medicine
Verified
Journal Article
Open access
JXJingjing Xiang
Jingjing Xiang
ZLZefei Li
Zefei Li
CWChaoyang Wang
Chaoyang Wang
This study aimed to explore the historical research progress on benign prostatic hyperplasia from the perspective of traditional Chinese medicine theory and the treatment of benign prostatic hyperplasia (BPH) with Qian Lie Xing Fang (QLXF) via the warming and tonifying of kidney yang, promotion of blood circulation, and clearing of meridians. First, network pharmacology analysis was used to screen and identify possible pathways for BPH treatment with QLXF. Subsequently, molecular docking analysis helped explore the mechanism of action by which the components of QLXF affected androgen receptor (AR) and type 5 phosphodiesterase inhibitor (PDE-5) levels. Targets for treatment with QLXF were identified from the online Mendelian inheritance in man and DisGeNET databases. BPH-related genes were identified using GeneCards and online Mendelian inheritance in man databases, and their intersection was used to construct a protein–protein interaction network analysis graph. Subsequently, gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were performed. The semiflexible docking of the ingredients of QLXF acting on the 2 targets was performed via molecular docking and molecular dynamics simulation, to elucidate the mechanism of action by which the active ingredients affect AR and PDE-5 levels further. This enabled us to explore the pattern of interactions between small active ingredient molecules, the target protein, and the stability after binding at the microscopic level. Gene ontology enrichment analysis showed that QLXF affected several processes, such as DNA transcription factor binding, kinase binding, protein homodimerization activity, protein structure domain-specific binding, and protein-coupled amine receptor activity in BPH patients. KEGG results showed that chemical carcinogenic reactive oxidative species and the JAK-STAT, Pl3k-Akt, FoxO, NF-κB, and other pathways were significantly enriched. Conducting molecular docking studies to investigate the interaction of active components from QLXF with AR and PDE-5, it was found that MOL002260 may possess the potential to inhibit PDE-5 activity, while MOL010578 may exhibit the capability to inhibit AR activity. QLXF is closely associated with various biological processes and KEGG signaling pathways related to BPH. The active ingredients of QLXF were investigated for their interactions with AR and PDE-5, with a primary focus on the small molecules MOL002260 and MOL010578.

29 December 2023 in Medicine
Verified
Journal Article
Open access
JXJingjing Xiang
Jingjing Xiang
ZLZefei Li
Zefei Li
QLQi Liu
Qi Liu
To explore the effective ingredients and mechanisms of action in Hedyotis diffusa (HD) that have inhibitory effects on androgen receptors (AR) using molecular docking and molecular dynamics simulations (MDS). The effective ingredients of HD were collected through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database and literatures. All components were docked with AR using Libdock. The receptor ligand interaction between the optimal ligand and AR were analyzed. Two simulation systems, namely I and II, containing AR and testosterone propionates (TP) were constructed, which System II contained the optimal ligand. The duration of the MDS was set to 300 ns. The distance between TP and AR peripheral active sites, root mean square deviation of ligand and receptor, receptor radius of gyration, distance between ligand center and binding site center, and ligand receptor binding energy were analyzed. 37 components of HD were collected, and the optimal ligand was MOL001656. MOL001656 forms hydrogen bonds with residues LEU48, PHE108, GLN55, LEU45, and ASN49 of AR. MDS have found that binding of TP to AR active sites can be observed in System I. The root mean square deviation of AR and MOL001656 both tended to stabilize in System II, with no significant fluctuations in the radius of gyration of AR and no significant fluctuations in the distance between ligand and binding cavity, indicating that the receptor ligand structure is relatively stable and their binding is relatively stable. The binding energy between AR and MOL001656 was −29.33 ± 3.84 kcal/mol. HD contains multiple effective ingredients that may have inhibitory AR activity. MOL001656 can occupy binding sites, thereby may exerting AR inhibitory effects.